Llwytho...

Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial

PURPOSE: Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both improve survival when commenced alongside standard of care (SOC) androgen deprivation therapy in locally advanced or metastatic hormone-sensitive prostate cancer. Thus, patient-reported quality of life (QOL) data m...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Oncol
Prif Awduron: Rush, Hannah L., Murphy, Laura, Morgans, Alicia K., Clarke, Noel W., Cook, Adrian D., Attard, Gerhardt, Macnair, Archie, Dearnaley, David P., Parker, Christopher C., Russell, J. Martin, Gillessen, Silke, Matheson, David, Millman, Robin, Brawley, Christopher D., Pugh, Cheryl, Tanguay, Jacob S., Jones, Robert J., Wagstaff, John, Rudman, Sarah, O'Sullivan, Joe M., Gale, Joanna, Birtle, Alison, Protheroe, Andrew, Gray, Emma, Perna, Carla, Tolan, Shaun, McPhail, Neil, Malik, Zaf I., Vengalil, Salil, Fackrell, David, Hoskin, Peter, Sydes, Matthew R., Chowdhury, Simon, Gilbert, Duncan C., Parmar, Mahesh K. B., James, Nicholas D., Langley, Ruth E.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2022
Pynciau:
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7612717/
https://ncbi.nlm.nih.gov/pubmed/34757812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.21.00728
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!